Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

09:35 ET COVID-19 Response Teaches Industry that Investing in Patient Partnership is Key to all Research Endeavors

While COVID-19 has severely affected many industries, scientific pursuit for a host of medical conditions is also threatened by sharply negative...


09:23 ET Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting on May 28-29, 2020

Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that...


09:15 ET Merck e Baylor College of Medicine estabelecem colaboração para desenvolver plataforma de produção de vacina contra a COVID-19

A Merck, empresa líder em ciência e tecnologia, e a Baylor College of Medicine, de Houston, Texas, EUA, anunciaram hoje uma extensão de sua...


09:15 ET Merck y el Baylor College of Medicine colaboran para desarrollar una plataforma de producción de vacunas para combatir el covid-19

Merck, una compañía líder en ciencia y tecnología, y el Baylor College of Medicine, Houston, Texas (Estados Unidos), anunciaron hoy una ampliación de ...


09:15 ET Merck y el Baylor College of Medicine colaboran para luchar contra el Covid-19

Merck, destacada compañía de ciencias y tecnología, y el Baylor College of Medicine, Houston, Texas, Estados Unidos, anunciaron hoy la ampliación de...


09:15 ET Merck et le Baylor College of Medicine collaborent pour poursuivre le développement d'une plateforme de fabrication de vaccins contre le Covid-19

Merck, une société de science et de technologie de premier plan, et le Baylor College of Medicine, de Houston, au Texas, États-Unis, ont annoncé...


09:15 ET Merck und Baylor College of Medicine kooperieren bei Weiterentwicklung einer Impfstoff-Herstellungs-plattform in Reaktion auf Covid-19

Merck, ein führendes Wissenschafts- und Technologieunternehmen, und das in Houston, Texas, USA, ansässige Baylor College of Medicine haben heute eine ...


09:15 ET MilliporeSigma and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19

MilliporeSigma and Baylor College of Medicine today announced an extension of their ongoing collaboration to advance a manufacturing platform to...


09:00 ET DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK's investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma

GlaxoSmithKline (GSK) plc today announced new data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical programme, which...


08:30 ET AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new safety and efficacy results for...


08:07 ET Ajinomoto Bio-Pharma Services firma un acuerdo de fabricación con Humanigen para Lenzilumab

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), destacado proveedor de servicios de desarrollo y fabricación biofarmacéuticos por contrato, se...


08:07 ET Ajinomoto Bio-Pharma Services signe un contrat de fabrication avec Humanigen concernant le lenzilumab, qui fait actuellement l'objet d'une étude de phase III approuvée par la FDA pour le COVID-19

Ajinomoto Bio-Pharma Services (« Aji Bio-Pharma »), fournisseur leader de services de fabrication et de développement biopharmaceutique sous contrat, ...


08:07 ET Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased ...


08:01 ET Scientists Uncover Ways HIV is Sexually Transmitted in Women

Women represent more than half of new cases of HIV infection worldwide, and most become infected by having sexual intercourse with an infected...


08:00 ET Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


07:30 ET Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)

Novartis announced today that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the...


07:00 ET Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Novartis today announced a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials, to be presented during the ASCO20...


07:00 ET MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the ...


07:00 ET BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled...


07:00 ET Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present new research from its schizophrenia portfolio at the American Society of Clinical...


07:00 ET Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity

Q32 Bio, a biotechnology company developing biologics to restore healthy immune regulation, today announced the company's pipeline and plans to enter ...


07:00 ET Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the...


05:00 ET Pregnancy reprograms breast cells, reducing cancer risk

An early age of pregnancy (25 years and younger) is known to reduce the overall risk of breast cancer by over 30%. CSHL Assistant Professor Camila...


03:00 ET Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

Cytovation AS ("Cytovation"), a clinical-stage biotechnology company focused on developing CyPep-1, a next-generation lytic immunotherapy, is pleased ...


03:00 ET Pneumagen Announces £4m Fundraising and Commits to Clinical Trial Development for COVID-19

Pneumagen (Holdings) Ltd, focused on treating infectious diseases by targeting the human glycome, today announced a GBP £4 million investment to...